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Stransplanted tissue-engineered graft. The first question we
wished to answer was as follows: What is the relative contri-
bution of the 2 cell types seeded onto the scaffold, and were
both cell types necessary for graft and recipient survival?
The study confirmed the applicability of the decellulariza-
tion, cell preparation, and reseeding techniques, as well as
the ease of application of our tracheal bioreactor. However,
attention should be paid during cell isolation and culture to
avoid contamination caused by fibrocyte proliferation. Nota-
bly, no animal demonstrated the development of local or sys-
temic rejection responses to any residual donor antigens, and
this was without the administration of immunosuppressive
medication. Zani and colleagues12 demonstrated in 2008
the potential of tissue healing and functional restoration if
epithelial and endothelial cells are present at the same
time, even with a lack of an ordered architectural relation-
ship. In our model these effects might be provided by resid-
ual MSCs in the MSC-derived chondrocyte culture,
inducing rapid angiogenesis and making the graft viable.
As Genden and associates13 showed in 2003, the necessity
of re-epithelialization is highly important for graft integrity
and for protection against a fibroproliferative response of
the recipient. Additionally, we showed that long-segment
grafts need to be seeded with epithelial cells before ortho-
topic transplantation to avoid bacterial/fungal contamina-
tion. Compared with our previous technically demanding
method of direct graft revascularization,6 the approach de-
scribed here makes the tracheal reconstruction much more
practicable and reproducible but nevertheless with an out-
standing outcome.
Gathering knowledge and information regarding the
strain abilities of a tracheal graft were disappointing.14,15
Only a few publications were helpful when designing the
tensile test; however, in vitro and in vivo findings did not
correlate with each other. Our strain tests showed no differ-
ence in biomechanical properties between decellularized
scaffolds before implantation, scaffolds seeded with both
cell types 60 days after implantation, and normal trachea.
Therefore one can assume that there would be no collapse
of such grafts. However, our tensile-testing device provided
only longitudinal forces, and therefore the true test followed
in vivo, when multidirectional forces were applied. Under
these conditions, grafts with no cells or only 1 cell type
failed to retain functional strength, leading to incompetent
airways.
In conclusion, this experimental study demonstrated for
the first time the necessity of both MSC-derived chondro-
cytes and epithelial cells to obtain a functional and proper
long-segment tracheal graft with clinical effect. These
findings and the applied method of tissue engineering
will help forward the reconstruction of the trachea in
human subjects. Further studies are required to elucidate
the angiogenesis mechanisms and interactions between
residual MSCs.442 The Journal of Thoracic and Cardiovascular SurgReferences
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Dr Yolonda Colson (Boston, Mass). I have no conflicts.
You are to be congratulated on doing an amazing job in getting
this to actually work, and I think that you have defined a very nice
clinical problem that currently does not have a great solution.
Having said that, I think there are a lot of obvious questions in
terms of longer-term follow-up and analysis. I have several
questions.
You have 4 different groups that fail for different reasons, except
group 4, which does well. Were those groups done sequentially,
meaning did you do all the animals in group 1, all the animals in
group 2, and so, on so that there is a learning curve in terms of
infection and how you do it, or were they randomized?
Dr Go. Yes, it was randomized.
Dr Colson. Therefore there were some in the different groups
done after your success in group 4?
Dr Go. Exactly.
Dr Colson. I read the article that you have submitted, and you
also talk about there being no evidence of rejection or reaction.
What was done to actually know that other than grossly looking
at it because you did a lot of biopsies and obtained a lot of bloodery c February 2010
Go et al Evolving Technology/Basic Sciencesamples in the article that you did not talk about here. Second, the
animals in group 4 were all killed at 60 days, which is a little less
than 1 month after group 3. Is 60 days significant? In terms of lon-
ger-term follow-up, does that help us clinically?
Dr Go. To answer the first question, we took blood samples for
analysis, as I mentioned in the presentation, to determine, for exam-
ple, swine leukocyte antigen and other information and the C-reac-
tive protein level. As for the rejection, I just mentioned the swine
leukocyte antigen.
Excuse me, what was the second question?
Dr Colson. The animals in group 4 were killed at 60 days rou-
tinely rather than seeing what their long-term
Dr Go. To my knowledge, 1 month in the pig is comparable
with 6 months in a human subject, which means 60 days in
a pig translates to 360 days in a human subject. However, this
is just follow-up for the middle term. I would not say this is for
the long-term result.The Journal of Thoracic and CaDr Colson. Have you seen that in your patient whose case was
published in Lancet?
Dr Go. Yes. Actually, after 3 months of follow-up, she is doing
fine.
Dr Frank C. Detterbeck (New Haven, Conn). You replaced
a 6-cm segment of trachea?
Dr Go. Yes.
Dr Detterbeck. Tell me about the respiratory endothelium. It
seems like that has been the problem with longer-segment tracheal
replacement. Unless I missed it, you were seeding with chondro-
cytes primarily, right?
Dr Go. Sorry, I did not hear the question.
Dr Detterbeck. You seeded your bioengineered grafts with
chondrocytes.
Dr Colson. On the outside and epithelium on the inside.
Dr Detterbeck. Epithelium on the inside. Okay. I missed that
part. Thank you.rdiovascular Surgery c Volume 139, Number 2 443
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